Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Global Medical Solutions Australia Pty Limited T/A Radpharm Scientific

Overview

The Therapeutic Goods Act 1989 was enacted to regulate therapeutic goods in Australia, ensuring they are safe, of high quality, and that their benefits outweigh any risks. This legislation was introduced to address the need for a comprehensive regulatory framework governing the supply, advertising, and importation of therapeutic goods. Enacted by the Australian Parliament, the Act aims to protect public health by maintaining stringent standards for therapeutic goods available in the market. In this instance, the Therapeutic Goods Administration, a division of the Department of Health, exercised its authority under the Act to consent to the importation and supply of a particular medical product that did not fully conform to the labelling requirements set out in the Therapeutic Goods Order No. 69. The consent was granted subject to specific conditions to ensure that healthcare providers and consumers are adequately informed about the product's storage conditions and other relevant differences.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Commonwealth of Australia’s Department of Health, applies to the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood and blood components. This Act governs the import, export, manufacture, and supply of therapeutic goods, ensuring that they meet quality, safety, and efficacy standards. The scope of the Act includes various entities such as pharmaceutical companies, medical device manufacturers, and healthcare providers, as well as the therapeutic goods themselves. The legislation applies nationally across Australia, ensuring a consistent regulatory framework throughout the Commonwealth, states, and territories. The Act also includes provisions for exemptions, exclusions, and thresholds, which can be further defined or modified through subordinate instruments. For instance, certain therapeutic goods or classes of goods may be subject to specific conditions or exemptions as determined by regulations or orders under the Act. In this particular case, the Act facilitated consent for the importation and supply of a specific product that does not fully conform to certain labelling requirements, subject to conditions that ensure consumer safety and appropriate information dissemination.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, provide the framework for the Therapeutic Goods Administration (TGA) to grant consent for the importation and supply of therapeutic goods that do not fully conform with Australian standards. In this instance, section 14 consent was provided for the importation and supply of disofenin powder for injection multidose vial, a product used in the production of Technetium (99mTc) under the brand name HEPATOLITE kit (AUST R 19146). The consent, granted on 20 April 2015, acknowledges that the product does not comply with the storage condition requirements outlined in paragraph 3(2)(j) of Therapeutic Goods Order No. 69 (TGO 69). However, the consent is valid only until the batch of the product is exhausted. Under the Act, the obligations imposed on the entities governed by this consent are primarily informational. The supplier, Global Medical Solutions Australia Pty Limited T/A Radpharm Scientific, must ensure that each affected batch of the product is accompanied by a ‘Dear Healthcare Provider’ letter and a copy of the Australian package insert. These documents must clearly state the differences between the imported product and the Australian approved version, and must emphasise the importance of adhering to Australian approved storage conditions. Additionally, the carton labels of the imported product, which are intended for the USA market, must be over-stickered with the Australian sponsor's details and the AUST R number to comply with local regulatory standards. Failure to comply with the conditions set forth in the consent may result in legal repercussions. Although specific offences and penalties are not detailed in the provided text, it is implied that any breach of the consent conditions could lead to enforcement actions under the Therapeutic Goods Act. The potential consequences could include fines, product recalls, or other regulatory sanctions imposed by the TGA. These penalties are intended to ensure that therapeutic goods supplied in Australia meet the necessary safety and quality standards.